scr.zacks.comZacks Small Cap Research - Home

Home Analyst Bios Research Reports Companies by Analyst Biotech - David Bautz, PhD Bank & Finance – Ann Heffron, CFA, CPA Biotech - John Vandermosten, CFA Special Situations – Ian Gilson, PhD, CFA Special Situations – Steven Ralston, CFA Med-Tech – Brian Marckx, CFA Technology – Lisa Thompson Technology - M. Marin Healthcare - Beth Senko, CFA Companies by Name Distribution Institutional Distribution Retail Distribution Social Media RSS Feeds Our Partners IR Firms Contact Subscribe Free Weekly Digest Zacks SCR Premium OUR MISSION Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report on these companies, bringing investors a unique opportunity to gain insight on small cap investments. Zacks SCR's goal is to produce high quality, institutional, research for the small cap portfolio. To access a complimentary copy of the most recent research report on any company we cover, please click the 'Coverage' tab. Latest Notes in the Press July 31, 2020 OIIM: O2Micro Hits Profitability and Positive EBITDA in Q2 July 30, 2020 NEXCF: NexTech Preannounces Q2, Showing Growth of 133% July 30, 2020 TSEM: The Pandemic Continues to Take its Toll On End User Demand Login module Invalid login, please try again. You have retries remaining before your account will be locked. Your account is locked and it will be unlocked automatically in minutes. User ID: Password: Remember my ID: Register Now Forgot your password? Email us at scr@zacks.com for assistance. OUR PROCESS The Zacks Small-Cap analyst team has an average of 20 years' experience in the investment field. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe. Zacks Small-Cap Research coverage includes a full initiation report that is a comprehensive overview of the company with valuation, recommendation, and financial statements. Analysts will typically publish research reports after the initiation on an as needed basis. Events that usually trigger publishing a research report or note include earnings, SEC filings, and material events. Zacks SCR will often publish a dozen reports on the companies we cover each year. We are also active on earnings conference calls and will often attend investment conferences and company sponsored events. OUR VALUATIONS Zacks SCR is a division of Zacks Investment Research (ZIR). ZIR is our parent company and also the parent company of Zacks.com . Zacks.com . has a stock rating service called the Zacks Rank. The Zacks Rank is a proprietary quantitative model that uses trends in earnings estimate revisions and EPS surprises to proportionally classify stocks into five groups: #1 = Strong Buy #2 = Buy #3 = Hold #4 = Sell #5 = Strong Sell. The Zacks Ranks is determined by Zacks Rank Analysis software and has been back-tested using over two decades of financial data. Zacks Rank is a very good predictor of both positive and negative earnings surprises.Zacks SCR valuations are 100% fundamental research driven evaluations of the company based on all available information, including fundamental market analysis using techniques such as SWOT and financial statement analysis. We at Zacks SCR would like investors to know that while the Zacks Rank is an important quant-driven trading tool, it is not fundamental stock research and investors looking for quality equity research analysis can rely on the Zacks SCR valuations found on this website . Zacks Full Access For full access to the Zacks Small Cap Research back catalogue, please visit our Subscribe page Latest Notes in the Press July 31, 2020 OIIM: O2Micro Hits Profitability and Positive EBITDA in Q2 July 30, 2020 NEXCF: NexTech Preannounces Q2, Showing Growth of 133% July 30, 2020 TSEM: The Pandemic Continues to Take its Toll On End User Demand July 30, 2020 NOVN: R&D Update for Molluscum July 28, 2020 CTSO: Strong Cash Position & Growing Database July 27, 2020 AZRX: Capital Raise, OPTION 2 Trial Underway July 27, 2020 ALQGC: Initiating Coverage on Quantum Genomics July 24, 2020 PBSV: Pharma-Bio Serv – Steady in an unpredictable world July 22, 2020 BTAI: Positive Results in SERENITY Trials Puts NDA Filing on Track for 1Q21… July 20, 2020 POETF: Disrupting Photonics Pricing and Functionality Through Innovation and Scalable Automation Invalid login, please try again. You have retries remaining before your account will be locked. Your account is locked and it will be unlocked automatically in minutes. User ID: Password: Remember my ID: COPYRIGHT © ZACKS INVESTMENT RESEARCH 2020 Disclaimer Privacy Policy Site Map Tweet Follow @ZacksSmallCap -- -- Powered By Q4 Inc. 5.39.0.1...